MEDX - ETF AI Analysis
Top Page
Horizon Kinetics Medical ETF (MEDX)
Rating:65Neutral
Price Target:―
Positive Factors
Established Healthcare Leaders
Many of the top holdings are large, well-known drug companies, which can provide stability within the medical sector.
Several Strong-Performing Core Stocks
Key positions like Johnson & Johnson, Novartis, Merck, Amgen, and Bristol-Myers Squibb have shown generally positive recent performance, helping support the fund.
Focused Exposure to Healthcare
The fund’s heavy tilt toward the health care sector gives investors targeted access to medical and pharmaceutical companies rather than a broad market mix.
Negative Factors
High Expense Ratio
The fund’s fees are relatively high for an ETF, which can eat into long-term returns.
Sector Concentration Risk
With most assets in health care and little exposure elsewhere, the ETF is vulnerable if the medical sector struggles.
Mixed Recent Performance
The ETF has seen weak year-to-date and recent one-month results, partly due to lagging holdings like AbbVie, AstraZeneca, Ionis, and Alnylam.
MEDX vs. SPDR S&P 500 ETF (SPY)
AUM18.17M
RegionGlobal
Expense Ratio0.85%
Beta0.62
IssuerHorizon Kinetics
Inception DateJan 30, 2023
Dividend Yield1.25%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume2,231
30 Day Avg. Volume2,646
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
42.34Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering31
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
MEDX Summary
The Horizon Kinetics Medical ETF (MEDX) is a health care fund that focuses on medical companies rather than tracking a specific index. It invests mainly in U.S. health care businesses across drugs, biotech, devices, and medical services. Well-known holdings include Eli Lilly and Johnson & Johnson. Someone might consider MEDX if they want long-term growth potential from medical innovation and an aging population, while still spreading money across many health care names instead of picking single stocks. A key risk is that it is heavily concentrated in the health care sector, so it can rise or fall sharply with changes in that industry.
How much will it cost me?The Horizon Kinetics Medical ETF (MEDX) has an expense ratio of 0.85%, meaning you’ll pay $8.50 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on specialized health care investments that require more research and expertise.
What would affect this ETF?The Horizon Kinetics Medical ETF (MEDX) could benefit from ongoing advancements in medical research, an aging global population driving demand for health care, and increased health awareness globally. However, challenges such as regulatory changes, patent expirations for major pharmaceutical companies, or economic downturns impacting health care spending could negatively affect its performance. With top holdings like Eli Lilly and AbbVie, the ETF's success is closely tied to the innovation and market conditions within the health care sector.
MEDX Top 10 Holdings
MEDX is heavily tilted toward big drugmakers, with Eli Lilly as the clear heavyweight—but Lilly has been losing steam lately, acting more like a brake than an engine. AbbVie and Ionis are also lagging, adding to the drag on near-term returns. On the brighter side, steadier giants like Johnson & Johnson, Merck, and Novartis have been quietly pulling their weight, helping balance out the bumps. With a global mix of U.S. and European pharma and biotech, this ETF is a focused bet on large, research-driven health care names.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 15.54% | $2.76M | $879.71B | 28.21% | 72 Outperform | |
| AbbVie | 8.36% | $1.49M | $364.90B | 17.48% | 66 Neutral | |
| Novartis | 7.41% | $1.32M | $276.82B | 48.31% | 80 Outperform | |
| Johnson & Johnson | 5.93% | $1.05M | $574.24B | 58.94% | 78 Outperform | |
| AstraZeneca | 5.43% | $963.95K | $311.06B | 44.19% | 80 Outperform | |
| Bristol-Myers Squibb | 5.13% | $912.13K | $117.44B | 8.67% | 78 Outperform | |
| Ionis Pharmaceuticals | 4.78% | $848.41K | $12.21B | 189.65% | 61 Neutral | |
| Amgen | 4.30% | $763.18K | $183.28B | 21.32% | 77 Outperform | |
| Alnylam Pharma | 4.20% | $745.58K | $42.38B | 42.44% | 60 Neutral | |
| Merck & Company | 4.12% | $731.90K | $294.91B | 51.08% | 80 Outperform |
MEDX Technical Analysis
Neutral
―
Price Trends
33.83
Negative
33.45
Negative
31.10
Positive
Market Momentum
-0.25
Negative
48.52
Neutral
78.45
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For MEDX, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 32.97, equal to the 50-day MA of 33.83, and equal to the 200-day MA of 31.10, indicating a neutral trend. The MACD of -0.25 indicates Negative momentum. The RSI at 48.52 is Neutral, neither overbought nor oversold. The STOCH value of 78.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MEDX.
MEDX Peer Comparison
Comparison Results
Performance Comparison
MEDX
Horizon Kinetics Medical ETF
32.82
9.02
37.90%
FMED
Fidelity Disruptive Medicine ETF
―
―
―
MEDI
Harbor Health Care ETF
―
―
―
TMED
T. Rowe Price Health Care ETF
―
―
―
JDOC
JPMorgan Healthcare Leaders ETF
―
―
―
BMED
Future Health ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents